Klacid (Clarithromycin) is a semisynthetic macrolide antibiotic, used to treat various bacterial infections, with bacteriostatic action. Klacid (Clarithromycin) binds to the 50s-subunit of the bacterial ribosome, causing suppression of bacterial protein synthesis. Klacid (Clarithromycin) acts mainly bacteriostatic, as well as bactericidal.
Klacid (Clarithromycin) inhibits protein synthesis in a microbial cell and is active against:
- gram-positive aerobic microorganisms - Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumonia, Listeria monocytogenes
- aerobic gram-negative microorganisms - Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoea, Legionella pneumophila, Helicobacter pylori
- advantageously intracellular microorganisms - Mycoplasma pneumonia, Chlamydia pneumonia (TWAR), Mycobacterium leprae, Mycobacterium kansaii, Mycobacterium chelonae, Mycobacterium fortitum, Mycobacterium avium complex (MAC), Mycobacterium intracellulare.
In vitro, Klacid (Clarithromycin) is active against most strains of the following microorganisms:
- aerobic gram-positive microorganisms - Streptococcus agalactiae, Streptococci (groups C, F, G), Streptococcus viridans
- aerobic gram-negative microorganisms - Bordetella pertussis, Pasteurella multocida, Campylobacter jejuni
- anaerobic gram-positive microorganisms - Clostridium perfringens, Peptococcus niger, Propionibacterium acnes
- anaerobic gram-negative microorganisms - Bacteroides melaninogenicus
- spirochete - Borrelia burgdorferi, Treponema pallidum.
Klacid (Clarithromycin) is well absorbed from the gastrointestinal tract. Eating slows down the absorption of Klacid (Clarithromycin), but does not affect the bioavailability of the active substance.
Approximately 20% of Klacid (Clarithromycin) is immediately metabolized to form the main metabolite of 14-hydrochlorithromycin.
- lower respiratory tract infections (bronchitis, pneumonia)
- upper respiratory tract infections (pharyngitis, sinusitis)
- infections of the skin and soft tissues (folliculitis, cellulitis, erysipelas)
- common mycobacterial infections caused by Mycobacterium avium and Mycobacterium intracellulare
- localized mycobacterial infections caused by Mycobacterium chelonae, Mycobacterium fortuitum and Mycobacterium kansasii
- Helicobacter pylori eradication and a decrease in the frequency of relapse of a duodenal ulcer
- Lyme disease
- prevention of the spread of infection due to the Mycobacterium avium complex (MAC) complex in HIV-infected patients with a CD4 lymphocyte count (T-helper lymphocytes) of not more than 100 in 1 mm3
- odontogenic infections.
- severe liver dysfunction
- severe renal impairment (CC <30 ml / min)
- simultaneous use with astemizole, cisapride, pimozide, terfenadine, ergotamine, dihydroergotamine
- pregnancy, lactation (breastfeeding)
- children's age up to 3 years (when using tablets)
- hypersensitivity to antibiotics of the macrolide group.
Klacid (Clarithromycin) should be used with caution in patients with impaired liver and kidney function.
CAS Number: 81103-11-9
Package: 10 tabs 500 mg.